The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Is interleukin‐1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy?
Abstract
Summary: The interleukin‐1 (IL‐1) family consists of two major agonistic proteins, IL‐1α and IL‐1β, which are pleiotropic and affect mainly inflammation, immunity, and hemopoiesis. The IL‐1 receptor antagonist (IL‐1Ra) is a physiological inhibitor of pre‐formed IL‐1. In their secreted form, IL‐1α and IL‐1β bind to the same receptors and induce the same biological functions. However, the IL‐1 molecules differ in their compartmentalization within the producing cell or the microenvironment. Thus, IL‐1β is solely active in its secreted form, whereas IL‐1α is mainly active in cell‐associated forms (intracellular precursor and membrane‐bound IL‐1) and only rarely as a secreted cytokine, mainly by macrophages/monocytes. IL‐1 is abundant at tumor sites, being produced by cellular elements of the tumor microenvironment or by the malignant cells, and it affects not only various phases of the malignant process, such as carcinogenesis, tumor growth, and invasiveness, but also patterns of interactions between malignant cells and the host's immune system. Hence, the effects of the IL‐1 molecules on the malignant process are complex and are often of an opposing nature. Comparative studies on the differential roles of malignant cell‐ or host‐derived IL‐1α and IL‐1β in different stages of the malignant process can subsequently open new avenues for manipulation of IL‐1 expression and function in cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
A cytokine-mediated link between innate immunity, inflammation, and cancer
Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940
Th17: An Effector CD4 T Cell Lineage with Regulatory T Cell Ties
Weaver, C. T., Harrington, L. E., Mangan, P. R., Gavrieli, M., & Murphy, K. M. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.002 · Cited by 1,422
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324
Yang, L., DeBusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., Matrisian, L. M., Carbone, D. P., & Lin, P. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.031 · Cited by 1,140
The P2X7 Receptor: A Key Player in IL-1 Processing and Release
Ferrari, D., Pizzirani, C., Adinolfi, E., Lemoli, R. M., Curti, A., Idzko, M., Panther, E., & Di Virgilio, F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.7.3877 · Cited by 1,025
Chen, C.-J., Kono, H., Golenbock, D., Reed, G., Akira, S., & Rock, K. L. (2007) · Nature Medicine · doi:10.1038/nm1603 · Cited by 876
Horai, R., Asano, M., Sudo, K., Kanuka, H., Suzuki, M., Nishihara, M., Takahashi, M., & Iwakura, Y. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.9.1463 · Cited by 611
Masquerader: High Mobility Group Box-1 and Cancer
Ellerman, J. E., Brown, C. K., de Vera, M., Zeh, H. J., Billiar, T., Rubartelli, A., & Lotze, M. T. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1953 · Cited by 355
Krelin, Y., Voronov, E., Dotan, S., Elkabets, M., Reich, E., Fogel, M., Huszar, M., Iwakura, Y., Segal, S., Dinarello, C. A., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2956 · Cited by 285
Self-citation
Cited by
Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Ridker, P., Lorenzatti, A., Krum, H., Varigos, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32247-x · Cited by 1,344
Bifidobacteria-mediated immune system imprinting early in life
Henrick, B. M., Rodriguez, L., Lakshmikanth, T., Pou, C., Henckel, E., Arzoomand, A., Olin, A., Wang, J., Mikes, J., Tan, Z., et al. (2021) · Cell · doi:10.1016/j.cell.2021.05.030 · Cited by 800
Bruchard, M., Mignot, G., Derangère, V., Chalmin, F., Chevriaux, A., Végran, F., Boireau, W., Simon, B., Ryffel, B., Connat, J. L., et al. (2013) · Nature Medicine · doi:10.1038/nm.2999 · Cited by 774
IL-1α and IL-1β Recruit Different Myeloid Cells and Promote Different Stages of Sterile Inflammation
Rider, P., Carmi, Y., Guttman, O., Braiman, A., Cohen, I., Voronov, E., White, M. R., Dinarello, C. A., & Apte, R. N. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102048 · Cited by 522
Self-citationInterleukin-1 Beta—A Friend or Foe in Malignancies?
Bent, R., Moll, L., Grabbe, S., & Bros, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082155 · Cited by 444
Metadata
- Authors
- Apte, R. N., & Voronov, E.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2008-03-19
- Volume
- 222
- Issue
- 1
- Pages
- 222-241
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2017316655
- Cited by
- 239
- References
- 11
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Is interleukin‐1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy? https://app.cochat.ai/papers/10.1111/j.1600-065x.2008.00615.x
- The paper
- Apte, R. N., & Voronov, E. (2008). Is interleukin‐1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy? Immunological Reviews. https://doi.org/10.1111/j.1600-065x.2008.00615.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.